Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 02/8/17 → 11/7/20 |
Funding
- Biothera Pharmaceuticals Incorporated: $44,908.00
A Multi-Center, Open-Label, Phase 2 Study of Imprime PGG and Pembrolizumab in Subjects With Advanced Melanoma Failing Front-Line Treatment With Checkpoint Inhibitors (CPI) or Triple Negative Breast Cancer (TNBC) Failing Front-Line Chemo...
- Stopeck, Alison (PI)
- Baer, Lea (CoPI)
- Cohen, Jules A (CoPI)
- Kudelka, Andrzej (CoPI)
Project: Research